Articles by Rachel Fischer, Ph.D., Senior Associate, Scientific Program and Grants Administration
UV Exposure & Risk of Cutaneous Melanoma in Skin of Color
By Rachel Fischer, Ph.D., Senior Associate, Scientific Program and Grants Administration | 14 April 2021 In News, Prevention, Science
In JAMA Dermatology, a team led by Adewole S. Adamson, MD, from The University of Texas at Austin, investigates whether there is an association, specifically in People of Color, between UV exposure and melanoma. MRA breaks down what this research means and how it should impact your sun safety practices.
Combination Therapy: Why Timing Might Be Everything
By Rachel Fischer, Ph.D., Senior Associate, Scientific Program and Grants Administration | 13 February 2020 In Science
About half of all melanomas have a mutated BRAF gene. This mutated gene makes an altered BRAF protein, which leads to the uncontrolled growth of melanoma cells. Drugs targeting these altered BRAF proteins, such as Vemurafenib and Dabrafenib have been approved for the treatment of BRAF+ melanoma.
About the Author
Rachel Fischer, Ph.D., Senior Associate, Scientific Program and Grants Administration
Rachel Fischer joined the Melanoma Research Alliance (MRA) as Senior Associate, Scientific Program and Grants Administration in December of 2019. In this role, she is responsible for the administrative management of MRA’s Grants Program, creating and supporting the development of written products, and coordinating MRA’s Annual Scientific Retreat. Rachel comes to MRA with more than 7 years of experience in biomedical research.
Rachel received her B.S. in Neuroscience from the University of St. Thomas and earned her Ph.D. in Pharmacology from Vanderbilt University. During graduate school, Rachel focused her studies on glaucoma, a condition of the eye, and the physiology of the cells that form the optic nerve. While at Vanderbilt, she also served as the VP of Communications for the Pharmacology Graduate Student Association. Additionally, she worked with the Health Research Alliance as the Members’ Meeting Program Coordinator and served as a Tennessee Advocacy Intern for the American Heart Association. Prior to graduate school, Rachel worked as a Junior Scientist at the University of Minnesota, studying the neurobiology of drug addiction.